Characteristics | CORRONA, n = 6263 | NinJa, n = 744 |
---|---|---|
Female | 4727 (75.8) | 589 (79.2) |
Race | ||
White | 5698 (91.0) | 0 (0.0) |
Black | 335 (5.3) | 0 (0.0) |
Others | 230 (3.7) | 744 (100.0) |
bDMARD | ||
TNF inhibitors | 5728 (91.5) | 586 (78.8) |
Non-TNF inhibitors | 535 (8.5) | 158 (21.2) |
MTX use | 3974 (63.5) | 516 (69.4) |
Dose among users, mg/week | 15 (10–20) | 8 (6–8) |
NSAID use | 3534 (56.4) | 303 (40.7) |
Glucocorticoid dose category | ||
0 mg | 5075 (81.0) | 463 (62.2) |
1–4 mg | 543 (8.7) | 193 (25.9) |
5–9 mg | 501 (8.0) | 77 (10.3) |
10+ mg | 144 (2.3) | 11 (1.5) |
Erosion* | 2690 (55.1) | 585 (81.8) |
Age, yrs, mean (SD) | 56.7 (13.5) | 56.3 (13.8) |
Age at RA onset, yrs, mean (SD) | 46.2 (14.1) | 47.0 (14.7) |
RA disease duration, yrs | 8.0 (4.0–15.0) | 6.0 (3.0–12.0) |
CDAI | 1.5 (0.8–2.2) | 1.6 (0.8–2.3) |
TJC, 0–28 | ||
0 | 5754 (91.9) | 641 (86.7) |
1 | 449 (7.2) | 84 (11.4) |
2 | 60 (1.0) | 14 (1.9) |
SJC, 0–28 | ||
0 | 5650 (90.2) | 622 (84.2) |
1 | 467 (7.5) | 91 (12.3) |
2 | 146 (2.3) | 26 (3.5) |
PtGA, 0–100 | 5.0 (2.0–12.0) | 5.0 (1.0–10.0) |
PGA, 0–100 | 4.0 (1.0–7.0) | 4.0 (1.0–7.0) |
BMI, kg/m2 | 27.2 (23.8–31.4) | 22.0 (20.1–24.1) |
Time since bDMARD, days | 174.5 (62.5–394.5) | 182.6 (182.6–547.9) |
Followup duration, days | 371.0 (189.8–777.0) | 365.2 (365.2–730.5) |
↵* Missing in 21% in CORRONA and 3% in NinJa. RA: rheumatoid arthritis; bDMARD: biological disease-modifying antirheumatic drugs; CORRONA: COnsortium of Rheumatology Researchers Of North America; NinJa: National Database of Rheumatic Diseases by iR-net in Japan; TNF: tumor necrosis factor; MTX: methotrexate; NSAID: nonsteroidal antiinflammatory drugs; CDAI: Clinical Disease Activity Index; TJC: tender joint count; SJC: swollen joint count; PtGA: patient’s global assessment; PGA: physician’s global assessment; BMI: body mass index.